Callan Capital LLC Buys New Shares in Gilead Sciences, Inc. (NASDAQ:GILD)

Callan Capital LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 4,629 shares of the biopharmaceutical company’s stock, valued at approximately $375,000.

Other institutional investors also recently modified their holdings of the company. Tompkins Financial Corp boosted its position in shares of Gilead Sciences by 223.1% in the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares during the period. OFI Invest Asset Management purchased a new position in Gilead Sciences during the 3rd quarter valued at about $26,000. Fortitude Family Office LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $29,000. Rakuten Securities Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $33,000. Finally, Financial Connections Group Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $40,000. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on GILD. Mizuho cut their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Barclays dropped their target price on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Monday, February 12th. Oppenheimer reiterated an “outperform” rating and set a $105.00 price target on shares of Gilead Sciences in a report on Friday, April 19th. Cantor Fitzgerald dropped their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. Finally, Wells Fargo & Company reduced their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. Eleven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $83.87.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded up $0.15 on Friday, hitting $65.42. 12,349,126 shares of the company were exchanged, compared to its average volume of 7,477,028. The company’s 50 day moving average price is $71.28 and its two-hundred day moving average price is $76.25. The firm has a market capitalization of $81.45 billion, a price-to-earnings ratio of 14.54, a PEG ratio of 1.20 and a beta of 0.19. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. Gilead Sciences, Inc. has a one year low of $64.63 and a one year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The firm had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. During the same quarter in the prior year, the firm posted $1.37 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. Research analysts expect that Gilead Sciences, Inc. will post 4.2 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were paid a $0.77 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.71%. Gilead Sciences’s dividend payout ratio is currently 68.44%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.